RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system

Journal of Controlled Release

Volumn 143, Issue 3, 2010, Pages 335-343

  Kim, Sung Wook ^a   Kim, Na Young ^a   Choi, Yu Bin ^a   Park, Seo Hyun ^a   Yang, Jai Myung ^a   Shin, Sungho ^a  

^a Sogang University   (South Korea)

Author keywords

Arginine peptide; SiRNA cellular location; SiRNA delivery system; Xenograft tumor model

Indexed keywords

ARGININE PEPTIDE; ARGININE PEPTIDES; BODY WEIGHT; COMPLEX SYSTEMS; DELIVERY SYSTEMS; FLUORESCENT LABELING; GENE SILENCING; IN-VITRO; IN-VIVO; LIVE CELL; MOUSE MODELS; PERINUCLEAR REGION; RNA INTERFERENCE; RNA-INDUCED SILENCING COMPLEXES; SIRNA DELIVERY; STABLE COMPLEXES; SUBCUTANEOUS TUMOR; TUMOR GROWTH; TUMOR MODELS;

AMINO ACIDS; COMPLEXATION; CONFOCAL MICROSCOPY; GENETIC ENGINEERING; NUCLEIC ACIDS; PEPTIDES; TUMORS;

RNA;

ARGININE PEPTIDE; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL NUCLEUS; CELL STRAIN COS7; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLUORESCENCE ANALYSIS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN RNA BINDING; RNA INTERFERENCE; SKIN TUMOR; WESTERN BLOTTING;

ANIMALS; ARGININE; CERCOPITHECUS AETHIOPS; COS CELLS; GENE THERAPY; GENES, ERBB-2; MICE; MICE, INBRED BALB C; NEOPLASMS; PEPTIDES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 77952241478     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.01.009     Document Type: Article

References (30)

1. Leng R.K., Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 2005, 107:222-239.
2. Hannon G.J., Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 2004, 431:371-378.
3. Amarzguioui M., Rossi J.J., Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett. 2005, 579:5974-5981.
4. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Genet. 2007, 8:173-184.
5. Fougerolles A., Vornlocher H.P., Maraganore J., Liberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Drug Discov. 2007, 6:443-453.
6. Martinez J., Patkaniowska A., Urlaub H., Luhrmann R., Tuschl T. Single stranded anti siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110:563-574.
7. Liu J., Carmell M.A., Rivas F.V., Marsden C.G., Thomson J.M., Song J.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305:1437-1441.
8. Rand T.A., Petersen S., Du F., Wang X. Argonaute2 cleaves the anti-guide stranded of siRNA during RISC activation. Cell 2005, 123:621-629.
9. Matranga C., Tomari Y., Shin C., Bartel D.P., Zamore P.D. Passenger-strand cleavage facilitates assembly of siRNA into AGO2-containing RNAi enzyme complexes. Cell 2005, 123:607-620.
10. Elbashir S.M., Lendeckel W., Tuschl T. RNA interferences is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15:188-200.
11. Akhtar S., Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. 2007, 59:164-182.
12. Behlke M.A. Progress towards in vivo use of siRNAs. Mol. Ther. 2006, 13:644-670.
13. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006, 2:711-719.
14. Nakamura Y., Kogure K., Futaki S., Harashima H. Octaarginine-modified multifunctional envelope-type nano device for siRNA. J. Control. Release 2007, 119:360-367.
15. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K. Arginine rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 2001, 276:5836-5840.
16. Kim H.H., Lee W.S., Yang J.M., Shin S. Basic peptide system for efficient delivery of foreign genes. Biochim. Biophys. Acta 2003, 1640:129-136.
17. Valentin F., Field M.C., Tippins J.R. The mechanism of oxidative stress stabilization of the thromboxane receptor in COS-7 cells. J. Biol. Chem. 2004, 279:8316-8324.
18. Kim S.H., Jeong J.H., Cho K.C., Kim S.W., Park T.G. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly (ethylenimine). J. Control. Release 2005, 104:223-232.
19. Choi H.S., Kim H.H., Yang J.M., Shin S. An insight into the gene delivery mechanism of the arginine peptide system: role of the peptide/DNA complexes size. Biochim. Biophys. Acta 2006, 1760:1604-1612.
20. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine-complexed siRNA in vivo. Gene Ther. 2005, 12:461-466.
21. Chiu Y.L., Ali A., Chu C.Y., Cao H., Rana T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi living cells. Chem. Biol. 2007, 11:1165-1175.
22. Wang Y.H., Hou Y.W., Lee H.J. An intracellular delivery method for siRNA by an arginine-rich peptide. J. Biochem Biophys Methods 2007, 70:579-586.
23. Simeoni F., Morris M.C., Heitz F., Divita G. Insight into the mechanism of the peptide-based gene delivery system: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003, 31:2717-2724.
24. Kim H.H., Choi H.S., Yang J.M., Shin S. Characterization of gene delivery in vitro and in vivo by the arginine peptide system. Int. J. Pharm. 2007, 335:70-78.
25. Veldhoen S., Laufer S.D., Trampe A., Restle T. Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res. 2006, 34:6561-6573.
26. Kim W.J., Christensen L.V., Jo S., Yockman J.W., Jeong J.H., Kim Y.H., Kim S.W. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 2006, 14:343-350.
27. Futaki S., Ohashi W., Suzuki T., Niwa M., Tanaka S., Ueda K., Harashima H., Sugiura Y. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug. Chem. 2001, 12:1005-1011.
28. Billy E., Brondani V., Zhang H., Muller U., Filipowicz W. Specific interference with gene expression induced by long double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:14428-14433.
29. Zeng Y., Cullen B.R. Influence in human cells is restricted to the cytoplasm. RNA 2002, 8:856-860.
30. El-Sayed A. IA.Khalil, K. Kogure, S. Futaki, H. Harashima, Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. J. Biol. Chem. 2008, 283:23450-23461.